loading page

Bortezomib Treatment of Steroid-Refractory Evans Syndrome in Children
  • +2
  • Serina Beydoun,
  • Yogindra Persaud,
  • Jennifer Lafferty,
  • Michael Callaghan,
  • Sureyya Savasan
Serina Beydoun
Children's Hospital of Michigan
Author Profile
Yogindra Persaud
Children's Hospital of Michigan
Author Profile
Jennifer Lafferty
Children's Hospital of Michigan
Author Profile
Michael Callaghan
Children's Hospital of Michigan
Author Profile
Sureyya Savasan
Wayne State University School of Medicine
Author Profile

Abstract

Treatment of refractory Evans syndrome (ES) remains a challenge in Hematology practice. Due to rarity of this condition, evidence-based approaches are limited and often treatment choices stem from small case series or anectodal experiences. Here, we describe three very refractory pediatric ES cases treated on bortezomib without adverse effects. Two of the three patients had dramatical and long-lasting recovery that started following the first doses of the drug. Clinical trials to assess bortezomib role in ES treatment are warrented and results may lead to inclusion of this drug as an option, even as a first-line therapy.

Peer review status:ACCEPTED

27 Jun 2020Submitted to Pediatric Blood & Cancer
27 Jun 2020Submission Checks Completed
27 Jun 2020Assigned to Editor
27 Jun 2020Reviewer(s) Assigned
17 Jul 2020Review(s) Completed, Editorial Evaluation Pending
17 Jul 2020Editorial Decision: Revise Major
16 Aug 2020Assigned to Editor
16 Aug 2020Submission Checks Completed
16 Aug 20201st Revision Received
17 Aug 2020Reviewer(s) Assigned
06 Sep 2020Review(s) Completed, Editorial Evaluation Pending
06 Sep 2020Editorial Decision: Revise Minor
09 Sep 20202nd Revision Received
09 Sep 2020Submission Checks Completed
09 Sep 2020Assigned to Editor
09 Sep 2020Review(s) Completed, Editorial Evaluation Pending
09 Sep 2020Editorial Decision: Accept